AbbVie Class Action Lawsuit (ABBV Lawsuit)
Levi & Korsinsky, LLP announces that a ABBV class action lawsuit (AbbVie Class Action Lawsuit) has been filed on behalf of investors who purchased AbbVie Inc. (ABBV) securities between April 30, 2021 and August 31, 2021. For more on the ABBV Lawsuit please contact us today.
According to the AbbVie Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
If you suffered a loss in AbbVie Inc. you have until June 6, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Deadline of Submission is Until June 6, 2022
AbbVie Class Action Lawsuit,
AbbVie Class Action,
ABBV Class Action Lawsuit,
ABBV Class Action,
AbbVie Inc. Class Action Lawsuit
AbbVie Inc. Lawsuit
ABBV Class Action Lawsuit
AbbVie Inc. (ABBV) Class Action Lawsuit